Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States

D. Kerrigan; A. Mantsios; R. Grant; M. Markowitz; P. Defechereux; M. La Mar; S. W. Beckham; P. Hammond; D. Margolis; M. Murray

doi:10.1007/s10461-017-2017-x

Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States

D. Kerrigan, A. Mantsios, R. Grant, M. Markowitz, P. Defechereux, M. La Mar, S. W. Beckham, P. Hammond, D. Margolis, M. Murray

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.

Original language	English (US)
Pages (from-to)	3540-3549
Number of pages	10
Journal	AIDS and behavior
Volume	22
Issue number	11
DOIs	https://doi.org/10.1007/s10461-017-2017-x
State	Published - Nov 1 2018

Keywords

HIV
Long-acting injectable
Men
PrEP
Providers
Qualitative
Risk behavior

ASJC Scopus subject areas

Social Psychology
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1007/s10461-017-2017-x

Fingerprint Dive into the research topics of 'Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States'. Together they form a unique fingerprint.

Cite this

Kerrigan, D., Mantsios, A., Grant, R., Markowitz, M., Defechereux, P., La Mar, M., Beckham, S. W., Hammond, P., Margolis, D., & Murray, M. (2018). Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. AIDS and behavior, 22(11), 3540-3549. https://doi.org/10.1007/s10461-017-2017-x

Expanding the Menu of HIV Prevention Options : A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. / Kerrigan, D.; Mantsios, A.; Grant, R.; Markowitz, M.; Defechereux, P.; La Mar, M.; Beckham, S. W.; Hammond, P.; Margolis, D.; Murray, M.

In: AIDS and behavior, Vol. 22, No. 11, 01.11.2018, p. 3540-3549.

Research output: Contribution to journal › Article › peer-review

Kerrigan, D, Mantsios, A, Grant, R, Markowitz, M, Defechereux, P, La Mar, M, Beckham, SW, Hammond, P, Margolis, D & Murray, M 2018, 'Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States', AIDS and behavior, vol. 22, no. 11, pp. 3540-3549. https://doi.org/10.1007/s10461-017-2017-x

Kerrigan, D. ; Mantsios, A. ; Grant, R. ; Markowitz, M. ; Defechereux, P. ; La Mar, M. ; Beckham, S. W. ; Hammond, P. ; Margolis, D. ; Murray, M. / Expanding the Menu of HIV Prevention Options : A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. In: AIDS and behavior. 2018 ; Vol. 22, No. 11. pp. 3540-3549.

@article{fe6e217fb4974d009a78b8c9f65354ba,

title = "Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States",

abstract = "Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study ({\'E}CLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.",

keywords = "HIV, Long-acting injectable, Men, PrEP, Providers, Qualitative, Risk behavior",

author = "D. Kerrigan and A. Mantsios and R. Grant and M. Markowitz and P. Defechereux and {La Mar}, M. and Beckham, {S. W.} and P. Hammond and D. Margolis and M. Murray",

note = "Funding Information: This study was funded by ViiV Healthcare. Funding Information: Conflict of interest Deanna Kerrigan received support via a GSK contract. Andrea Mantsios received support via a GSK contract. Robert Grant was an investigator on trials supported in part by ViiV/GSK. Martin Markowitz was an investigator on trials supported in part by ViiV/GSK. Patricia Defechereux was staff on trials supported in part by ViiV/GSK. Melissa La Mar was staff on trials supported in part by ViiV/GSK. Sarah Beckham received support via a GSK contract. Paige Hammond received support via a GSK contract. David Margolis is an employee of ViiV Healthcare. Miranda Murray is an employee of ViiV Healthcare.",

year = "2018",

month = nov,

day = "1",

doi = "10.1007/s10461-017-2017-x",

language = "English (US)",

volume = "22",

pages = "3540--3549",

journal = "AIDS and Behavior",

issn = "1090-7165",

publisher = "Springer New York",

number = "11",

}

TY - JOUR

T1 - Expanding the Menu of HIV Prevention Options

T2 - A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States

AU - Kerrigan, D.

AU - Mantsios, A.

AU - Grant, R.

AU - Markowitz, M.

AU - Defechereux, P.

AU - La Mar, M.

AU - Beckham, S. W.

AU - Hammond, P.

AU - Margolis, D.

AU - Murray, M.

N1 - Funding Information: This study was funded by ViiV Healthcare. Funding Information: Conflict of interest Deanna Kerrigan received support via a GSK contract. Andrea Mantsios received support via a GSK contract. Robert Grant was an investigator on trials supported in part by ViiV/GSK. Martin Markowitz was an investigator on trials supported in part by ViiV/GSK. Patricia Defechereux was staff on trials supported in part by ViiV/GSK. Melissa La Mar was staff on trials supported in part by ViiV/GSK. Sarah Beckham received support via a GSK contract. Paige Hammond received support via a GSK contract. David Margolis is an employee of ViiV Healthcare. Miranda Murray is an employee of ViiV Healthcare.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.

AB - Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.

KW - HIV

KW - Long-acting injectable

KW - Men

KW - PrEP

KW - Providers

KW - Qualitative

KW - Risk behavior

UR - http://www.scopus.com/inward/record.url?scp=85039736006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039736006&partnerID=8YFLogxK

U2 - 10.1007/s10461-017-2017-x

DO - 10.1007/s10461-017-2017-x

M3 - Article

C2 - 29290075

AN - SCOPUS:85039736006

VL - 22

SP - 3540

EP - 3549

JO - AIDS and Behavior

JF - AIDS and Behavior

SN - 1090-7165

IS - 11

ER -